Axe Compute Inc. annual report, FY2023

Filing identity and reporting period

Important discrepancy: The request identifies Axe Compute Inc., but the supplied filing is Predictive Oncology Inc.’s Form 10-K (NASDAQ: POAI). It reports the fiscal year ended December 31, 2023, with 2022 comparative figures; it is not a standalone fourth-quarter report.

Business context

Predictive Oncology operates three business segments: Pittsburgh, applying AI and tumor-sample data to oncology drug development and providing 3D tumor models; Birmingham, providing biologics formulation and protein research services; and Eagan, selling the FDA-cleared STREAMWAY medical-fluid waste system and related products.

Financial performance and liquidity

Revenue rose about 18% year over year, while gross margin declined two percentage points, primarily due to costs of Pittsburgh contracted services. Eagan contributed $1.14 million of 2023 revenue; Pittsburgh contributed $493,000 and Birmingham $152,000. Revenue remained small relative to operating expenses.

General and administrative expense fell to $9.43 million from $11.11 million, mainly reflecting lower staff-related costs and amortization. Operations expense increased to $4.13 million, and sales and marketing expense increased to $1.51 million. The smaller net loss versus 2022 largely reflects the absence of 2022 goodwill and finite-lived intangible impairment charges, not a return to profitability.

At December 31, 2023, current assets were $10.08 million and current liabilities were $3.95 million. Total liabilities were $6.15 million, including $2.71 million of operating lease liabilities and a $150,408 short-term note bearing 9.25% interest. Stockholders’ equity was $8.27 million. The company reported no financing transactions during 2023; financing cash flow was $149,000, mainly from premium financing, net of repayments.

Changes, outlook, risks and unusual items

• Net loss improved by $11.75 million year over year, chiefly because 2022 included $7.23 million of goodwill impairment and $3.35 million of intangible-asset impairment. In 2023, the company recorded $163,000 of property-and-equipment impairment in Birmingham and no goodwill or finite-lived intangible impairment.
• Cash declined by $13.34 million during 2023. Management said it does not expect near-term operating revenue to sustain operations and is evaluating equity, debt, other financing, or asset/business monetization. The filing provides no specific revenue, earnings, or cash-flow guidance.
• The auditor and management disclosed substantial doubt about the company’s ability to continue as a going concern within one year after the financial statements were issued. Additional financing may be unavailable or dilutive; without adequate funding, the company may have to curtail operations, default on obligations, or liquidate.
• Key risks include continued cash burn, limited commercial traction in newer oncology businesses, uncertain AI performance and adoption, competition, sole-source suppliers, regulatory changes affecting laboratory-developed tests, intellectual-property protection, and potential Nasdaq listing compliance.
• The company’s 2023 Section 382 tax analysis limited and reduced a substantial portion of its tax-loss carryforwards. Management reported that material weaknesses in accounting resources and IT general controls identified in 2022 and 2023 were remediated by year-end 2023; it concluded internal control over financial reporting and disclosure controls were effective as of December 31, 2023. The auditor did not attest to internal-control effectiveness.
• After year-end, Chief Business Officer Pamela Bush left effective February 15, 2024; the company agreed to pay $410,000 over the following twelve months.

Most important facts for investors to verify

1. Confirm the issuer: the supplied filing is Predictive Oncology Inc., not Axe Compute Inc.
2. Assess the going-concern warning against the company’s $8.73 million year-end cash, $13.19 million 2023 operating cash outflow, and financing alternatives.
3. Check subsequent financing, liquidity, and operating developments not covered by this 2023 year-end filing.
4. Evaluate revenue quality and concentration: one customer accounted for $490,000 of 2023 Pittsburgh-segment revenue.
5. Review potential dilution: 1,806,589 warrants were outstanding at year-end, alongside equity awards and future financing needs.
6. Verify the status of LDT regulation, Nasdaq listing compliance, and the effectiveness of the reported control remediations.